Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2023)

RedHill Biopharma has reported Non-Current Deffered Revenue over the past 6 years, most recently at $540000.0 for Q4 2023.

  • Quarterly Non-Current Deffered Revenue fell 28.0% to $540000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $540000.0 through Dec 2023, down 28.0% year-over-year, with the annual reading at $540000.0 for FY2023, 28.0% down from the prior year.
  • Non-Current Deffered Revenue was $540000.0 for Q4 2023 at RedHill Biopharma, down from $750000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $750000.0 in Q4 2020 and troughed at $500000.0 in Q4 2019.
  • The 5-year median for Non-Current Deffered Revenue is $750000.0 (2020), against an average of $658000.0.
  • Year-over-year, Non-Current Deffered Revenue soared 50.0% in 2020 and then decreased 28.0% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $500000.0 in 2019, then soared by 50.0% to $750000.0 in 2020, then changed by 0.0% to $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then decreased by 28.0% to $540000.0 in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Non-Current Deffered Revenue are $540000.0 (Q4 2023), $750000.0 (Q4 2022), and $750000.0 (Q4 2021).